Risk factors for fractures following liver transplantation: a population-based cohort study

References

• Yang LS, Shan LL, Saxena A, et al. Liver transplantation: a systematic review of long-term quality of life. Liver Int. 2014;34(9):1–10. doi: 10.1111/liv.12553.
   Web of Science ®Google Scholar
• Krol CG, Dekkers OM, Kroon HM, et al. Longitudinal changes in BMD and fracture risk in orthotopic liver transplant recipients not using bone-modifying treatment. J Bone Miner Res. 2014;29(8):1763–1769. doi: 10.1002/jbmr.2214.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Aguilar EF, Pérez-Escobar J, Sánchez Herrera D, et al. Bone disease and liver transplantation: a review. Transplant Proc. 2021;53(7):2346–2353. doi: 10.1016/j.transproceed.2021.07.049.
   PubMed Web of Science ®Google Scholar
• Nakchbandi IA. Osteoporosis and fractures in liver disease: relevance, pathogenesis and the therapeutic implications. World J Gastroenterol. 2014;20(28):9427–9438.
   PubMed Web of Science ®Google Scholar
• Ruiz-Gaspà S, Dubreuil M, Guañabens N, et al. Ursodeoxycholic acid decreases bilirubin-induced osteoblast apoptosis. Eur J Clin Invest. 2014;44(12):1206–1214. doi: 10.1111/eci.12355.
   PubMed Web of Science ®Google Scholar
• Stokes CS, Volmer DA, Grünhage F, et al. Vitamin D in chronic liver disease. Liver Int. 2013;33(3):338–352. doi: 10.1111/liv.12106.
   PubMed Web of Science ®Google Scholar
• Fusaro M, Cianciolo G, Brandi ML, et al. Vitamin K and osteoporosis. Nutrients. 2020;12(12):3625. doi: 10.3390/nu12123625.
   PubMed Web of Science ®Google Scholar
• Huldén E, Castedal M, Karlsson MK, et al. Osteoporosis in cirrhotics before and after liver transplantation: relation with malnutrition and inflammatory status. Scand J Gastroenterol. 2020;55(3):354–361. doi: 10.1080/00365521.2020.1735507.
   PubMed Web of Science ®Google Scholar
• Compston JE. Osteoporosis after liver transplantation. Liver Transpl. 2003;9(4):321–330. doi: 10.1053/jlts.2003.50044.
   PubMed Web of Science ®Google Scholar
• Sung JL. Hepatitis B virus infection and its sequelae in Taiwan. Gastroenterol Jpn. 1984;19(4):363–366. doi: 10.1007/BF02779126.
   PubMedGoogle Scholar
• Bennett H, Waser N, Johnston K, et al. A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan. Hepatol Int. 2015;9(3):378–390. doi: 10.1007/s12072-015-9629-x.
   PubMed Web of Science ®Google Scholar
• Chen YY, Fang WH, Wang CC, et al. Crosssectional assessment of bone mass density in adults with hepatitis B virus and hepatitis C virus infection. Sci Rep. 2019;9(1):5069. doi: 10.1038/s41598-019-41674-4.
   PubMedGoogle Scholar
• Wijarnpreecha K, Thongprayoon C, Panjawatanan P, et al. Hepatitis C virus infection and risk of osteoporosis: a meta-analysis. Saudi J Gastroenterol. 2017;23(4):216–221. doi: 10.4103/sjg.SJG_452_16.
   PubMed Web of Science ®Google Scholar
• Cheng CL, Kao YH, Lin SJ, et al. Validation of the national health insurance research database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf. 2011;20(3):236–242. doi: 10.1002/pds.2087.
   PubMed Web of Science ®Google Scholar
• Chang SL, Huang YL, Lee MC, et al. Association of varicose veins with incident venous thromboembolism and peripheral artery disease. JAMA. 2018;319(8):807–817. doi: 10.1001/jama.2018.0246.
   PubMed Web of Science ®Google Scholar
• Chen HP, Tsai YF, Lin JR, et al. Recipient age and mortality risk after liver transplantation: a population-based cohort study. PLoS ONE. 2016;11(3):e0152324. doi: 10.1371/journal.pone.0152324.
   PubMed Web of Science ®Google Scholar
• Hagström H, Adams LA, Allen AM, et al. Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement. Hepatology. 2021;74(1):474–482. doi: 10.1002/hep.31726.
   PubMed Web of Science ®Google Scholar
• Yadav A, Carey EJ. Osteoporosis in chronic liver disease. Nutr Clin Pract. 2013;28(1):52–64. doi: 10.1177/0884533612470145.
   PubMed Web of Science ®Google Scholar
• Sinclair M, Grossmann M, Gow PJ, et al. Testosterone in men with advanced liver disease: abnormalities and implications. J Gastroenterol Hepatol. 2015;30(2):244–251. doi: 10.1111/jgh.12695.
   PubMed Web of Science ®Google Scholar
• Khosla S, Oursler MJ, Monroe DG. Estrogen and the skeleton. Trends Endocrinol Metab. 2012;23(11):576–581. doi: 10.1016/j.tem.2012.03.008.
   PubMed Web of Science ®Google Scholar
• Cheng CH, Chen LR, Chen KH. Osteoporosis due to hormone imbalance: an overview of the effects of estrogen deficiency and glucocorticoid overuse on bone turnover. Int J Mol Sci. 2022;23(3):1376. doi: 10.3390/ijms23031376.
   PubMed Web of Science ®Google Scholar
• Isoniemi H, Appelberg J, Nilsson CG, et al. Transdermal oestrogen therapy protects postmenopausal liver transplant women from osteoporosis. A 2-year follow-up study. J Hepatol. 2001;34(2):299–305. doi: 10.1016/s0168-8278(00)00067-2.
   PubMed Web of Science ®Google Scholar
• Lim LY, Chalasani N. Vitamin D deficiency in patients with chronic liver disease and cirrhosis. Curr Gastroenterol Rep. 2012;14(1):67–73. doi: 10.1007/s11894-011-0231-7.
   PubMedGoogle Scholar
• Kaemmerer D, Schmidt B, Lehmann G, et al. Monthly ibandronate for the prevention of bone loss in patients after liver transplantation. Transplant Proc. 2012;44(5):1362–1367. doi: 10.1016/j.transproceed.2012.01.133.
   PubMed Web of Science ®Google Scholar
• Ho OTW, Ng WCA, Ow ZGW, et al. Bisphosphonate therapy after liver transplant improves bone mineral density and reduces fracture rates: an updated systematic review and meta-analysis. Transpl Int. 2021;34(8):1386–1396. doi: 10.1111/tri.13887.
   PubMed Web of Science ®Google Scholar
• Jeong HM, Kim DJ. Bone diseases in patients with chronic liver disease. Int J Mol Sci. 2019;20(17):4270. doi: 10.3390/ijms20174270.
   PubMed Web of Science ®Google Scholar
• Doyard M, Chappard D, Leroyer P, et al. Decreased bone formation explains osteoporosis in a genetic mouse model of hemochromatosiss. PLoS One. 2016;11(2):e0148292. doi: 10.1371/journal.pone.0148292.
   PubMed Web of Science ®Google Scholar
• Wilson T, Katz JM, Gray DH. Inhibition of active bone resorption by copper. Calcif Tissue Int. 1981;33(1):35–39. doi: 10.1007/BF02409410.
   PubMed Web of Science ®Google Scholar
• Yilmaz Y. Review article: non-alcoholic fatty liver disease and osteoporosis-clinical and molecular crosstalk. Aliment Pharmacol Ther. 2012;36(4):345–352. doi: 10.1111/j.1365-2036.2012.05196.x.
   PubMed Web of Science ®Google Scholar
• Parés A, Guañabens N. Primary biliary cholangitis and bone disease. Best Pract Res Clin Gastroenterol. 2018;34-35:63–70. doi: 10.1016/j.bpg.2018.06.005.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Dauriz M, Gatti D, et al. Systematic review with meta-analysis: non-alcoholic fatty liver disease is associated with a history of osteoporotic fractures but not with low bone mineral density. Aliment Pharmacol Ther. 2019;49(4):375–388. doi: 10.1111/apt.15087.
   PubMed Web of Science ®Google Scholar
• Wester A, Hagström H. Risk of fractures and subsequent mortality in non-alcoholic fatty liver disease: a nationwide population-based cohort study. J Intern Med. 2022;292(3):492–500. doi: 10.1111/joim.13497.
   PubMed Web of Science ®Google Scholar
• Lin JC, Hsieh TY, Wu CC, et al. Association between chronic hepatitis C virus infection and bone mineral density. Calcif Tissue Int. 2012;91(6):423–429. doi: 10.1007/s00223-012-9653-y.
   PubMed Web of Science ®Google Scholar
• Baeg MK, Yoon SK, Ko SH, et al. Males seropositive for hepatitis B surface antigen are at risk of lower bone mineral density: the 2008–2010 Korea national health and nutrition examination surveys. Hepatol Int. 2016;10(3):470–477. doi: 10.1007/s12072-015-9672-7.
   PubMed Web of Science ®Google Scholar
• Byrne DD, Newcomb CW, Carbonari DM, et al. Risk of hip fracture associated with untreated and treated chronic hepatitis B virus infection. J Hepatol. 2014;61(2):210–218. doi: 10.1016/j.jhep.2014.04.001.
   PubMed Web of Science ®Google Scholar
• Hansen AB, Omland LH, Krarup H, et al. Fracture risk in hepatitis C virus infected persons: results from the DANVIR cohort study. J Hepatol. 2014;61(1):15–21. doi: 10.1016/j.jhep.2014.03.007.
   PubMed Web of Science ®Google Scholar
• Chotiyarnwong P, McCloskey EV. Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat Rev Endocrinol. 2020;16(8):437–447. doi: 10.1038/s41574-020-0341-0.
   PubMed Web of Science ®Google Scholar
• Buckley L, Humphrey MB. Glucocorticoid-induced  osteoporosis. N Engl     J Med.   2018;379(26):2547–2556.  doi: 10.1056/NEJMcp1800214.
   PubMed Web of Science ®Google Scholar
• Sosa M, Gómez de Tejada MJ. Glucocorticoid-induced osteoporosis. N Engl J Med. 2019;380(14):1378–1379.
   PubMed Web of Science ®Google Scholar
• Wada C, Kataoka M, Seto H, et al. High-turnover osteoporosis is induced by cyclosporin A in rats. J Bone Miner Metab. 2006;24(3):199–205. doi: 10.1007/s00774-005-0672-x.
   PubMed Web of Science ®Google Scholar
• Kanda J, Izumo N, Furukawa M, et al. Effects of the calcineurin inhibitors cyclosporine and tacrolimus on bone metabolism in rats. Biomed Res. 2018;39(3):131–139. doi: 10.2220/biomedres.39.131.
   PubMed Web of Science ®Google Scholar
• Monegal A, Navasa M, Guañabens N, et al. Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. Calcif Tissue Int. 2001;68(2):83–86. doi: 10.1007/BF02678145.
   PubMed Web of Science ®Google Scholar
• Song L, Xie XB, Peng LK, et al. Mechanism and treatment strategy of osteoporosis after transplantation. Int J Endocrinol. 2015;2015:280164. doi: 10.1155/2015/280164.
   PubMed Web of Science ®Google Scholar